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Reply to Herigon and Newland
To the Editor—We appreciate the interest of Herigon and
Newland1 in our trial of Staphylococcus aureus decolonization
measures in patients with community-associated skin and
soft-tissue infections.2 These authors raise an important issue
in the reporting of randomized controlled trials that has been
a source of much debate and has received considerable attention: handling missing outcomes in intention-to-treat
(ITT) analyses.
The lack of a clear definition for the term “intention to
treat” has resulted in inconsistencies in the reporting of clinical trials.3,4 The Cochrane Handbook for Systematic Reviews
of Interventions 5 describes 3 principles of ITT analysis, although the application of all criteria is not clearly agreed
upon: (1) analyzing participants in their randomized intervention group, regardless of whether the assigned intervention actually occurred (which is generally accepted); (2) measuring outcome data for all participants (which is nearly
impossible); and (3) analyzing all randomized participants
(which may involve imputing data for participants with missing outcomes). Some trials use other analytic methods, including “per-protocol” analysis, which includes only participants who were known to comply with the allocated
intervention and who completed the trial, and “treatmentreceived” or “as-treated” analysis, in which participants, regardless of their randomization assignment, are analyzed by
the intervention that was performed.5
As earlier CONSORT (Consolidated Standards of Reporting Trials) guidelines6 recommended the use of ITT analysis
when analyzing randomized trial data, the term “modified
ITT analysis” is now being utilized with increasing frequency
to reflect missing outcome data or protocol deviations.7 As

Herigon and Newland (and others) point out, the meaning
of the term “modified ITT” is not uniformly applied.5,7 Indeed, a more accurate definition of the analyses performed
in our trial is “available case analysis,” in which only participants with outcome data available at longitudinal study visits
were included and participants were analyzed in the arm to
which they were assigned, regardless of compliance with the
assigned regimen.5,7 Of note, the revised CONSORT 2010
statement requests that trial reports include whether the analysis was conducted by retaining participants in their originally
assigned groups, replacing the prior guidance to report
whether an “intention-to-treat” analysis was conducted.8
As no consensus exists for handling missing data in ITT
analyses, clinical trial experts recommend designing and conducting studies in a manner that minimizes losses to followup.3,4 Our patient population had a high prevalence of predictors of attrition reported in prior studies;9 10% of our
study participants reported not having a permanent home,
and 15% and 51% reported having no health insurance or
public health insurance, respectively. Strategies to maximize
retention included a 2-staged enrollment process, flexible
scheduling, cash remuneration for time and travel, and obtaining multiple phone numbers and contact information for
people close to participants.9
Missing data in clinical trials is largely inevitable. However,
the interpretation of missing outcome values is controversial
and can be addressed in several ways. One method is to
impute values for the missing data, assuming that all participants lost to follow-up experienced the event or did not
experience the event.5 Herigon and Newland examined our
data with one extreme assumption: that all participants lost
to follow-up remained colonized with S. aureus. Analyzing
the data with the opposite assumption, in which all participants with missing data were eradicated of S. aureus colonization, supports our original findings determined by available case analysis (Table 1). However, as suggested by Herigon
and Newland, imputation of missing values with either the
best or the worst case value results in biased results and is
often too extreme.10 Another method for imputation of missing values is “last observation carried forward” (LOCF). Of
note, a patient’s colonization status after any intervention is
confounded by multiple factors (eg, exposure to other colonized household members, interval antibiotics), and spontaneous decolonization without intervention may occur in
up to 50% of participants.11 In addition, colonization was a
requirement for study enrollment. Thus, we believe that the
LOCF method would introduce additional bias into our study
(Table 1). Ultimately, statistical techniques cannot adequately
compensate for missing values.5 The missing data in our study
are considered “missing completely at random” (MCAR), and
the available case analysis approach is a valid interpretation
of outcomes data if the MCAR assumption is met.5,10 Logistic
regression analysis, including demographic and epidemiologic
factors, was performed to detect significant differences between patients with and without missing longitudinal data.
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32/57 (56)
.400
1.16
0.82–1.63

35/62 (56)
.030
1.51
1.02–2.12

LOCF

50/75 (67) 35/75 (47)
.180
.622
1.19
1.10
0.92–1.54 0.77–1.56

48/75 (64) 35/75 (47)
.033
.066
1.37
1.38
1.02–1.84 0.96–1.97

ITT
Available eradication
case analysis imputed

Education and mupirocin

31/57 (54)
.510
1.12
0.79–1.58

35/64 (55)
.050
1.46
0.99–2.15

LOCF

49/75 (65) 37/75 (49)
.242
.413
1.17
1.16
0.90–1.51 0.82–1.64

46/75 (61) 35/75 (47)
.071
.066
1.31
1.46
0.97–1.78 0.97–2.20

ITT
Available eradication
case analysis imputed

Education, mupirocin,
and chlorhexidine

36/51 (71)
.020
1.46
1.07–1.98

34/54 (63)
.006
1.68
1.15–2.44

LOCF

60/75 (80) 38/75 (51)
.002
.326
1.43
1.18
1.13–1.80 0.84–1.68

55/75 (73) 34/75 (45)
.001
.094
1.57
1.42
1.19–2.07 0.94–2.14

ITT
Available eradication
case analysis imputed

Education, mupirocin,
and bleach baths

note. Data are proportion (%) of participants in whom S. aureus carriage was eradicated. The hygiene-education-only (control) group was used as the comparator group to determine
relative risk (RR) and P values. P values represent comparisons between the intervention group and the control group. “Available case analysis” represents the original analysis performed
for the randomized clinical trial.2 “ITT eradication imputed” represents an analysis in which patients lost to follow-up were assumed to be eradicated of S. aureus carriage. “LOCF”
represents an analysis in which colonization status at the prior time point was imputed for missing data at the subsequent longitudinal samplings. ITT, intention to treat; LOCF, last
observation carried forward; CI, confidence interval.

1 month after intervention
Proportion (%)
P value
RR
95% CI
4 months after intervention
Proportion (%)
P value
RR
95% CI

ITT
Available eradication
case analysis imputed

Hygiene education only

table 1. Eradication of Staphylococcus aureus Carriage
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At 1 month after the intervention, age was a significant predictor of attrition, with older individuals being more likely
to remain in the study; however, this association did not
persist at 4 months (data not shown).
Interestingly, participants randomized to the control group
(receiving only personal and household hygiene education)
had the highest retention. This was an open trial, and patients
were aware of the 4 potential randomization arms. Other
investigators have observed the phenomenon in which study
retention was higher if the perceived benefits of the study
outweighed the burdens and risks of the intervention or the
condition being treated.9,12 As participants in the intervention
arms received decolonization measures at enrollment, they
may not have perceived added benefit in returning for followup visits for colonization culturing and survey completion.
In contrast, participants in the control arm may have been
hopeful that they would eventually receive decolonization
measures if they continued in the study, although this was
never suggested to them.
We believe that the data generated by this trial provide
evidence for a regimen already prescribed by many practitioners and, as many questions remain, serve as a foundation
for future trials.
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